XTL Competitors

XTLB Stock

ILS 5.90 0.10 1.72%

XTL Biopharmaceuticals competes with Nice, Gold Bond, Bank Leumi, ICL Israel, and Mizrahi Tefahot; as well as few others. Analyzing XTL Biopharmaceutica competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of XTL Biopharmaceutica to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out XTL Biopharmaceutica Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of XTL Biopharmaceutica competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.30	5.90	12.23

Details

Intrinsic

Valuation

Low	Real	High
0.28	5.69	12.02

Details

XTL Biopharmaceutica Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between XTL Biopharmaceutica and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of XTL and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of XTL Biopharmaceuticals does not affect the price movement of the other competitor.

	NICE	GOLD	LUMI	ICL	MZTF	AZRG	ESLT	DSCT	ORA	RATI
NICE		0.4	0.51	0.4	0.56	0.52	0.47	0.48	0.36	0.52	NICE
GOLD	0.4		0.89	0.79	0.86	0.85	0.9	0.9	-0.15	0.86	GOLD
LUMI	0.51	0.89		0.87	0.96	0.92	0.93	0.99	0.08	0.98	LUMI
ICL	0.4	0.79	0.87		0.78	0.72	0.74	0.87	-0.25	0.83	ICL
MZTF	0.56	0.86	0.96	0.78		0.97	0.95	0.97	0.26	0.97	MZTF
AZRG	0.52	0.85	0.92	0.72	0.97		0.95	0.93	0.29	0.93	AZRG
ESLT	0.47	0.9	0.93	0.74	0.95	0.95		0.94	0.15	0.93	ESLT
DSCT	0.48	0.9	0.99	0.87	0.97	0.93	0.94		0.07	0.98	DSCT
ORA	0.36	-0.15	0.08	-0.25	0.26	0.29	0.15	0.07		0.14	ORA
RATI	0.52	0.86	0.98	0.83	0.97	0.93	0.93	0.98	0.14		RATI
	NICE	GOLD	LUMI	ICL	MZTF	AZRG	ESLT	DSCT	ORA	RATI

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

DSCT	+ 0.99	LUMI
RATI	+ 0.98	LUMI
RATI	+ 0.98	DSCT
AZRG	+ 0.97	MZTF
DSCT	+ 0.97	MZTF
RATI	+ 0.97	MZTF

High negative correlations

ORA	- 0.25	ICL
ORA	- 0.15	GOLD

Risk-Adjusted Indicators

There is a big difference between XTL Stock performing well and XTL Biopharmaceutica Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze XTL Biopharmaceutica's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
NICE	1.80	(0.01)	0.00	0.05	0.00	0.00	3.73	(3.08)	21.85
GOLD	1.16	0.47	0.22	(0.81)	1.01	(1.41)	4.04	(2.42)	8.05
LUMI	1.18	0.37	0.22	20.84	1.12	(1.30)	2.55	(2.11)	5.36
ICL	1.91	0.29	0.11	(0.41)	1.80	(2.17)	5.63	(3.16)	11.77
MZTF	1.12	0.28	0.21	(2.16)	0.90	(1.40)	2.77	(1.86)	5.51
AZRG	1.47	0.37	0.21	(1.08)	1.29	(1.86)	3.76	(2.53)	9.70
ESLT	1.25	0.38	0.26	(3.10)	0.92	(1.46)	3.87	(2.02)	8.80
DSCT	1.29	0.39	0.24	8.52	1.16	(1.46)	2.59	(2.44)	7.16
ORA	1.07	(0.10)	0.00	(0.33)	0.00	0.00	2.04	(2.18)	9.28
RATI	1.39	0.36	0.23	1.58	1.14	(1.66)	3.55	(2.08)	8.86

Unable to evaluate fundamental data of [NICE.TA, GOLD.TA, LUMI.TA, ICL.TA, MZTF.TA, AZRG.TA, ESLT.TA, DSCT.TA, ORA.TA, RATI.TA] at this time. Please try again later

All Fundamental Data

XTL Biopharmaceutica Competitive Analysis

The better you understand XTL Biopharmaceutica competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, XTL Biopharmaceutica's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across XTL Biopharmaceutica's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	XTLB	NICE	GOLD	LUMI	ICL	MZTF	AZRG	ESLT	DSCT	ORA
	1.72 5.90 XTL	0.41 63,950 Nice	2.69 17,030 Gold	1.05 4,232 Bank	0.73 1,800 ICL	0.44 15,860 Mizrahi	2.77 30,100 Azrieli	0.16 95,100 Elbit	0.52 2,467 Israel	2.04 25,490 Ormat
Market Volatility (90 Days Market Risk)	Unstable	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Very Weak	Very Strong	Solid	OK	Solid	Good	Solid	Solid	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Quite High	Low	Low	Below Average	Low	Below Average	Below Average	Low	Below Average	Low
Current Valuation (Equity Enterprise Value)	Fairly Valued	Over Valued	Over Valued	Under Valued	Over Valued	Fairly Valued	Over Valued	Over Valued	Under Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Strong Sell	Hold	Strong Buy	Strong Sell	Cautious Hold	Sell	Hold	Strong Buy	Hold
Current Ratio	51.07	1.94	2.05	N/A	1.52	N/A	0.83	1.12	N/A	1.57
Net Asset	N/A	4.66 B	N/A	656.45 B	11.08 B	392.27 B	42.37 B	9.32 B	335.09 B	4.43 B
Profit Margin	N/A	0.12	21.1	0.41	0.21	0.33	1.25	0.0361	0.26	0.0927
EBITDA	(940 K)	448 M	37.73 M	N/A	1.8 B	N/A	4.13 B	576.93 M	N/A	186.21 M
Current Valuation	61.84 M	40.59 B	512.7 M	(111.82 B)	43.75 B	(31.1 B)	42 B	29.61 B	(16.3 B)	23.51 B
Operating Margin	N/A	0.15	17.4	0.58	0.34	0.52	0.66	0.059	0.39	0.25
Price To Book	N/A	4.3	154.25	0.92	2.0	1.32	1.36	2.86	1.03	2.75
Current Asset	N/A	655.15 M	147 M	80.2 B	2.98 B	44.27 B	2.94 B	2.47 B	32.45 B	N/A
Retained Earnings	N/A	N/A	224 M	22.44 B	2.5 B	10.6 B	11.34 B	N/A	9.84 B	N/A
Five Year Return	N/A	N/A	2.06	N/A	3.53	N/A	2.0	1.34	N/A	N/A
Beta	1.03	0.28	0.38	0.39	0.41	0.49	0.32	-0.0038	0.67	0.49
Number Of Employees	3	7.1 K	14	64	12.5 K	7.63 K	391	17.79 K	8.04 K	1.39 K
Shares Outstanding	514.21 M	63.53 M	N/A	1.47 B	1.29 B	257.18 M	121.27 M	44.34 M	1.24 B	56.09 M
Cash Flow From Operations	(1.05 M)	461.82 M	22.92 M	5.2 B	1.06 B	4.13 B	1.36 B	416.93 M	4.46 B	258.82 M
Annual Yield	N/A	N/A	N/A	0.0322	0.12	0.0315	0.0249	0.0122	0.0336	0.0051
Total Debt	N/A	429.27 M	108.04 M	31.13 B	2.44 B	30.25 B	13.71 B	884.95 M	12.3 B	1.52 B
Return On Equity	0.38	0.0863	9.41	0.15	0.43	0.18	0.18	0.0778	0.13	0.0401
Z Score	N/A	68.4	N/A	0.6	8.4	N/A	0.6	16.8	0.6	7.2
Return On Asset	-0.1	0.0433	3.29	0.0104	0.19	0.0103	0.0277	0.0218	0.009	0.0252
Book Value Per Share	0.009	45.74	76.82	32.64	4.12	89.51	178.47	58.67	19.49	32.95
Current Liabilities	N/A	399.06 M	39 M	350.44 B	2.05 B	178.58 B	5.95 B	1.95 B	178.51 B	N/A
Total Asset	N/A	4.66 B	381 M	656.45 B	11.08 B	392.27 B	42.37 B	9.32 B	335.09 B	4.43 B
Debt To Equity	N/A	0.3	34.6	N/A	0.67	N/A	66.0	0.63	N/A	87.3
Target Price	N/A	273.37	N/A	40.32	9.13	146.0	293.67	210.0	25.54	N/A
Last Dividend Paid	N/A	N/A	2.27	1.12	0.9	3.66	5.36	2.0	0.5	0.48
Shares Owned By Institutions	N/A	12.1	N/A	43.62	25.12	30.05	4.39	21.74	51.2	89.2
Market Capitalization	236.53 K	49.19 B	48.04 B	43.72 B	34.72 B	29.86 B	26.04 B	25.54 B	22.53 B	18.27 B
Price To Earning	558.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings To Growth	N/A	1.97	N/A	0.82	168.1	1.49	-0.79	91.95	0.42	5.19
Price To Sales	N/A	20.69	354.71	2.63	3.31	2.42	10.11	4.73	2.0	24.3
Net Income	435 K	199.22 M	28.58 M	6.03 B	783 M	3.19 B	2.89 B	274.35 M	2.77 B	62.09 M
Earnings Per Share	N/A	12.88	7.05	4.63	5.67	15.75	30.35	15.52	2.56	4.11
Shares Owned By Insiders	16.2	N/A	N/A	N/A	44.9	41.57	69.86	49.15	N/A	0.23
Revenue	N/A	1.92 B	135.42 M	15.49 B	6.96 B	10.25 B	2.21 B	5.28 B	10.43 B	663.08 M
Working Capital	N/A	256.09 M	108 M	(270.24 B)	939 M	(134.31 B)	(3 B)	519 M	(146.07 B)	N/A
Cash And Equivalents	5.06 M	1.56 B	79.75 M	93.51 B	492 M	51.29 B	2.42 B	219.15 M	24.75 B	79.37 M
Cash Per Share	0.01	24.75	19.67	62.6	0.38	219.6	19.96	4.96	21.26	1.56
Gross Profit	N/A	1.3 B	46.59 M	15.83 B	2.61 B	10.6 B	1.62 B	1.36 B	11.18 B	248.79 M
Day Typical Price	5.93	63830.0	17093.33	4260.0	1800.0	15876.67	29896.67	95816.67	2473.0	25456.67
Accumulation Distribution	13143.42	831.66	127.91	28877.92	21007.27	2114.41	7852.93	0.0272	17772.48	4005.48
Market Facilitation Index	N/A	0.0165	0.31	1.0E-4	0.0	0.0013	0.0043	2650.0	0.0	0.0082
Daily Balance Of Power	1.0	0.2766	(0.57)	(0.54)	0.3611	(0.33)	0.802	0.0566	(0.36)	0.5543
Period Momentum Indicator	0.1	260.0	(470.00)	(45.00)	13.0	(70.00)	810.0	150.01	(13.00)	510.0
Rate Of Daily Change	1.02	1.0	0.97	0.99	1.01	1.0	1.03	1.0	0.99	1.02
Day Median Price	5.95	63770.0	17125.0	4274.0	1800.0	15885.0	29795.0	96175.0	2476.0	25440.0
Price Action Indicator	N/A	310.0	(330.00)	(64.50)	6.5	(60.00)	710.0	(1,000.00)	(15.50)	305.0
Coefficient Of Variation	(700.42)	(9,209)	356.47	383.56	919.22	469.08	522.22	452.81	408.82	(1,817)
Mean Deviation	3.46	1.8	1.16	1.18	1.91	1.12	1.47	1.25	1.29	1.07
Jensen Alpha	(0.79)	(0.01)	0.4672	0.3662	0.2854	0.284	0.3718	0.3826	0.3868	(0.10)
Total Risk Alpha	(1.03)	(0.16)	0.3771	0.3041	0.1539	0.2205	0.2762	0.302	0.3176	(0.15)
Sortino Ratio	N/A	N/A	0.2227	0.2216	0.1128	0.2143	0.2085	0.2618	0.2406	N/A
Downside Variance	N/A	N/A	3.45	2.25	4.09	1.31	2.44	1.72	2.16	N/A
Standard Deviation	5.46	2.76	1.63	1.45	2.51	1.36	1.93	1.76	1.63	1.47
Kurtosis	8.7	8.41	1.13	(0.41)	1.07	(0.63)	1.5	1.68	0.7941	2.34
Potential Upside	9.23	3.73	4.04	2.55	5.63	2.77	3.76	3.87	2.59	2.04
Treynor Ratio	(5.75)	0.0507	(0.81)	20.84	(0.41)	(2.16)	(1.08)	(3.10)	8.52	(0.33)
Maximum Drawdown	33.31	21.85	8.05	5.36	11.77	5.51	9.7	8.8	7.16	9.28
Variance	29.85	7.6	2.67	2.09	6.29	1.84	3.74	3.09	2.65	2.16
Market Risk Adjusted Performance	(5.74)	0.0607	(0.80)	20.85	(0.40)	(2.15)	(1.07)	(3.09)	8.53	(0.32)
Risk Adjusted Performance	(0.11)	(0)	0.2294	0.2129	0.0938	0.1746	0.159	0.182	0.2007	(0.04)
Skewness	(1.24)	(1.21)	0.2944	(0.33)	0.9437	0.1845	0.5095	1.05	0.3095	(0.34)
Semi Deviation	N/A	N/A	1.01	1.12	1.8	0.9041	1.29	0.9172	1.16	N/A
Information Ratio	(0.15)	(0.03)	0.2531	0.2298	0.091	0.1802	0.1684	0.1954	0.2171	(0.09)
Value At Risk	(7.69)	(3.08)	(2.42)	(2.11)	(3.16)	(1.86)	(2.53)	(2.02)	(2.44)	(2.18)
Expected Short fall	N/A	N/A	(1.41)	(1.30)	(2.17)	(1.40)	(1.86)	(1.46)	(1.46)	N/A
Downside Deviation	N/A	N/A	1.86	1.5	2.02	1.14	1.56	1.31	1.47	N/A
Semi Variance	N/A	N/A	1.01	1.27	3.22	0.8174	1.65	0.8413	1.34	N/A

XTL Biopharmaceutica Competition Performance Charts

Five steps to successful analysis of XTL Biopharmaceutica Competition

XTL Biopharmaceutica's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by XTL Biopharmaceuticals in relation to its competition. XTL Biopharmaceutica's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of XTL Biopharmaceutica in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact XTL Biopharmaceutica's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to XTL Biopharmaceuticals, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your XTL Biopharmaceutica position

In addition to having XTL Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Cap ETFs Thematic Idea Now

Large Cap ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 686 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in XTL Stock

XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC